Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises

  • Agreement covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart
  • Over 400 million people worldwide have diabetes and the amount of insulin required to treat type 2 diabetes alone is expected to increase by more than 20% from 2018 to 2030[1],[2]
  • Sandoz continues to strategically expand their biosimilars portfolio, with eight marketed biosimilars and a robust pipeline, showing ongoing commitment to accessible innovation

…

/by

Sandoz teams up to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)

  • Strategic collaboration agreement with Curetis subsidiary Ares Genetics to develop digital platform for development and life-cycle management of antibiotics
  • Program will combine established microbiology laboratory techniques with advanced bioinformatics and AI methods
  • Short-term focus on repurposing existing antibiotics to treat infections involving multi-drug-resistant pathogens

Holzkirchen, December 18, 2018 – Sandoz today announces the signature of a strategic collaboration agreement with Ares Genetics GmbH, to …

/by

Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder

  • reSET-OTM is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder
  • Pear Therapeutics is leading the development of a new therapeutic class with two FDA-authorized PDTs and a robust pipeline of therapeutics across disease areas
  • Sandoz will lead U.S. commercial launch, anticipated in coming days in Q4
  • As part of broader Novartis digital revolution, Sandoz aims to increase patient engagement and improve access to treatment through digital solutions

…

/by

Sandoz certified Top Employer Asia Pacific 2019

  • Sandoz has been certified by the Top Employers Institute for its exceptional employee offerings in Asia Pacific (APAC)
  • The annual, international research undertaken by the Top Employers Institute recognizes leading employers around the world
  • This exclusive certification underlines Sandoz´ commitment to build a great place to work

Holzkirchen, December 4, 2018 – Sandoz, a Novartis division, has been certified “TOP Employer Asia Pacific 2019” for its exceptional employee offerings in the region. Sandoz is certified in five Asia …

/by